OncoMatch/Clinical Trials/NCT06508099
Vitamin A and D Supplementation in Allogeneic HCT
Is NCT06508099 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Vitamin A and Vitamin D3 for acute lymphoblastic leukemia.
Treatment: Vitamin A · Vitamin D3 — The therapy under investigation is the addition of 300 000 IU of vitamin A and 100 000 IU of vitamin D before conditioning. The study will include patients with malignant diseases in hematologic response with indications for allogeneic transplantation with matched related or matched unrelated donor.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Non-Hodgkin Lymphoma
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Prior therapy
Cannot have received: allogeneic transplantation of hematopoietic cells
Repeated allogeneic transplantation of hematopoietic cells
Lab requirements
Kidney function
creatinine more than 2 norms [excluded]; Creatinine clearance below 60ml/min/1.73m2 [excluded]
Liver function
ALT, AST more than 5 norms; bilirubin more than 1.5 normal [excluded]
Cardiac function
Severe cardiac pathology, including a decrease in ejection fraction <50%, unstable angina, exertional angina of III-IV functional class, heart failure of III-IV functional class, arrhythmia grade V according to Lawn [excluded]
Severe organ failure: creatinine more than 2 norms; ALT, AST more than 5 norms; bilirubin more than 1.5 normal; Creatinine clearance below 60ml/min/1.73m2; Severe cardiac pathology, including a decrease in ejection fraction <50%, unstable angina, exertional angina of III-IV functional class, heart failure of III-IV functional class, arrhythmia grade V according to Lawn
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify